Jeffrey Velotta | Medicine | Best Researcher Award

Dr. Jeffrey Velotta | Medicine | Best Researcher Award

Thoracic Surgeon | Kaiser Permanente Northern California | United States

Dr. Jeffrey Velotta, MD, FACS, is a highly accomplished thoracic surgeon and academic leader recognized for his contributions in lung cancer, mesothelioma, and thoracic surgical innovation. He serves as Associate Thoracic Surgeon at Kaiser Permanente Oakland Medical Center, where he directs the Northern California Mesothelioma Program. In parallel, he is Clinical Professor at Kaiser Permanente Bernard J. Tyson School of Medicine, Assistant Professor of Surgery at UCSF, and Global Faculty Member at Stanford University’s Center for Asian Health Research and Education. Dr. Velotta has earned recognition for his outstanding mentorship, teaching, and clinical care, while maintaining a strong presence in research addressing lung cancer disparities in Asian American populations. His leadership extends into numerous national committees, editorial boards, and professional societies, shaping policy and advancing education in thoracic surgery. His career integrates patient-centered care, surgical excellence, mentorship, and innovative research that collectively advance thoracic oncology and health equity.

Profile

Scopus

Orcid

Education

Dr. Jeffrey Velotta completed his undergraduate studies at the University of California, Santa Barbara, earning a Bachelor of Science degree in Physiology with honors. He pursued medical education at The George Washington University School of Medicine, graduating with distinction and election to the Alpha Omega Alpha Honor Society. His post-graduate surgical training included internship and residency in General Surgery at UCLA David Geffen School of Medicine, where he served as Chief Resident and received recognition for teaching excellence. He subsequently completed a postdoctoral research fellowship in Cardiothoracic Surgery at Stanford University School of Medicine under Dr. Robert C. Robbins. His advanced surgical training culminated with a residency and chief residency in Thoracic Surgery at Harvard Medical School’s Brigham and Women’s Hospital. This educational foundation, spanning leading institutions in California and Massachusetts, provided him with comprehensive expertise in general, cardiothoracic, and thoracic surgery, research methodology, and leadership in academic medicine.

Professional Experience

Dr. Jeffrey Velotta has established a distinguished career blending clinical practice, academic medicine, mentorship, and research. At Kaiser Permanente Oakland Medical Center, he serves as Associate Thoracic Surgeon and directs the Northern California Mesothelioma Program, leading multidisciplinary approaches for complex thoracic cancers. He is Clinical Professor at the Kaiser Permanente Bernard J. Tyson School of Medicine and Assistant Professor of Surgery at UCSF, where he actively teaches, mentors, and guides future surgeons. At Stanford University’s Center for Asian Health Research and Education, he contributes as Global Faculty, advancing population-based studies. His experience includes leadership roles in medical education, admissions committees, and national thoracic societies. He has mentored dozens of medical students, residents, fellows, and junior faculty, many of whom have progressed to prominent academic and clinical roles. His work spans surgery, mentorship, and health equity research, demonstrating his commitment to advancing thoracic oncology while training the next generation of physician leaders.

Awards and Honors

Dr. Jeffrey Velotta has received numerous awards recognizing excellence in surgery, mentorship, teaching, and research. His accolades include election as Fellow of the American College of Surgeons, induction into the American Association of Thoracic Surgeons, and honors from the Society of Asian Academic Surgeons. He has earned multiple UCSF Academy of Medical Educators awards for teaching and mentorship, as well as faculty teacher of the year recognition from UCSF-East Bay. Nationally, he has been awarded by the Society of Thoracic Surgeons, American College of Surgeons, and professional groups for leadership and contributions to clinical practice. His recognition extends to Castle Connolly Top Doctor designations, Reviewer of the Year awards for thoracic journals, and leadership development awards. Early in his career, he received young investigator and surgical excellence awards at Harvard and UCLA. These honors highlight his sustained contributions across clinical care, medical education, surgical innovation, and advancing health equity.

Research Focus

Dr. Jeffrey Velotta research focuses on lung cancer, mesothelioma, and thoracic surgical innovation, with a special emphasis on cancer disparities in Asian American populations. He has led multiple funded projects investigating lung cancer risk among Asian female non-smokers, equitable biomarker testing, outcomes of robotic and minimally invasive thoracic surgery, and strategies to improve access to lung cancer screening. His studies also explore guideline-concordant care, patient outcomes across diverse health systems, and innovative treatments such as cryoablation in mesothelioma surgery. At Stanford CARE, he advances Asian American health research, integrating clinical data with population-level insights. His collaborative work spans industry-funded trials, community health grants, and national cancer consortiums. As an editorial board member and peer reviewer for leading thoracic journals, he contributes to shaping academic discourse in his field. His research program embodies a blend of clinical practice, population health, and translational science aimed at reducing disparities and improving thoracic oncology care.

Publication

Chest Wall Reconstruction Using Biologic Mesh to Cover Soft Tissue Defects: A Narrative Review
Year: 2025

The Impact of Preoperative Invasive Nodal Staging on Unexpected Mediastinal Upstaging in Early-Stage Non-small Cell Lung Cancer
Year: 2025

Time to surgery in early-stage non–small cell lung cancer: Defining the optimal diagnosis-to-resection interval to reduce mortality
Year: 2025

Racial/Ethnic Disparities in Lung Cancer Surgery Outcomes in the USA
Year: 2025

Elevated risk of lung cancer among Asian American women who have never smoked: an emerging cancer disparity
Year: 2025

Conclusion

Dr. Jeffrey Velotta is highly suitable for recognition through this research award. His career embodies the integration of clinical excellence, impactful research, and dedicated mentorship. His contributions to advancing thoracic oncology, particularly in addressing disparities among Asian American populations, represent both innovation and social responsibility. With a strong track record of funded research, academic leadership, and peer recognition, he stands out as a leader whose work continues to shape the future of thoracic surgery and cancer care. His trajectory demonstrates both current excellence and potential for continued advancement, making him an exemplary candidate for this distinction.

 

Yuchun Wei | Medicine and Health Sciences | Best Researcher Award

Assoc. Prof. Dr. Yuchun Wei | Medicine and Health Sciences | Best Researcher Award

Shandong Cancer Hospital China

Dr. Yuchun Wei is a leading Chinese physician-scientist in the field of oncology and nuclear medicine, currently working at the Shandong Cancer Hospital in Jinan, China. Born on November 22, 1987, she has contributed significantly to developing innovative imaging techniques for cancer diagnosis, staging, and individualized treatment planning. With deep expertise in PET/CT imaging biomarkers, she is committed to advancing precision oncology. 📡🧬

Profile

Scopus

Orcid

🎓 Education

Dr. Wei pursued her academic journey with a strong foundation in both Western and traditional Chinese medicine:

  • Ph.D. in Oncology from Shandong University (2018–2022), mentored by Academician Jinming Yu 🎓
  • Master’s in Oncology from Jinan University (2013–2016), under Prof. Shuanghu Yuan 🔬
  • Bachelor’s in Traditional Chinese and Western Clinical Medicine from Shandong University of Traditional Chinese Medicine (2007–2012) 🌿

💼 Professional Experience

Dr. Wei currently serves as a radiotherapy physician at Shandong Cancer Hospital (2017–present). She has also held several administrative and research leadership roles:

  • Deputy Director, MDT Quality Management Office (2021–2022)
  • Assistant Director, Radioimmunity and Molecular Imaging Room (2020–2021)
    Her clinical expertise is complemented by her operational leadership in multidisciplinary cancer care. 🏥⚕️

🔬 Research Interests

Her research revolves around novel imaging techniques, especially FAPI-based PET/CT imaging, with a focus on early detection, prognosis prediction, and therapy monitoring for cancers such as lung, esophageal, and cervical. Her goal is to refine personalized cancer treatment through quantitative imaging biomarkers. 🔍📊

🏆 Awards & Honors

Dr. Wei has been nominated for multiple research and innovation awards in recognition of her work in molecular imaging and radiation oncology. Her studies have earned significant visibility in top-tier journals (JCR Q1), and she is regarded as a rising star in clinical translational imaging. 🌟

📚 Publications Top Notes: 

Dr. Wei has authored and co-authored over 17 high-impact peer-reviewed papers, most of which appear in JCR Q1 journals. Here are her key publications with direct links and citation highlights:

FAPI Compared with FDG PET/CT for Lung Cancer Diagnosis
Radiology, 2023, IF: 19.7 | Cited by: 33

18F-FAPI PET/CT in Esophageal SCC Response Prediction
J Nucl Med, 2024, IF: 9.1 | Cited by: 12

Early Detection of Radiation-Induced Myocardial Damage
Eur J Nucl Med Mol Imaging, 2023, IF: 10.057 | Cited by: 40

18F-FAPI PET/CT Response in Chemoradiotherapy for ESCC
J Nucl Med, 2023, IF: 11.082 | Cited by: 25

Biodistribution and Targeting of 18F-FAPI-04
Eur J Nucl Med Mol Imaging, 2022, IF: 10.057 | Cited by: 37

Differentiating Lung Cancer Types via PET/CT
Eur J Nucl Med Mol Imaging, 2022, IF: 10.057 | Cited by: 31

Baseline Angiogenesis in NSCLC Prognosis
J Transl Med, 2022, IF: 8.44 | Cited by: 19

Differentiating Inflammatory Lung Lesions with FAPI
Eur Radiol, 2023, IF: 5.9 | Cited by: 10

Comparison Study in Mouse Model using PET Imaging
Sci Rep, 2016, IF: 5.228 | Cited by: 50

Radiation-Induced Lung Damage Model in Rats
Front Oncol, 2022, IF: 5.738 | Cited by: 14